Serum miR-210 contributes to tumor detection, stage prediction and dynamic surveillance in patients with bladder cancer

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Yang, Yongmei ^a   Qu, Ailin ^a   Liu, Jingkang ^a   Wang, Rui ^a   Liu, Yingjie ^a   Li, Gang ^b   Duan, Weili ^a   Fang, Qian ^a   Jiang, Xiumei ^a   Wang, Lili ^a   Zheng, Guixi ^a   Du, Lutao ^a   Zhang, Xin ^a   Wang, Chuanxin ^a  

^a SHANDONG UNIVERSITY   (China)

^b Department of Urology Honggang Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 210; COMPLEMENTARY DNA; MICRORNA; MIRN210 MICRORNA, HUMAN; TUMOR MARKER;

ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; FEMALE; GENE CONTROL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICRORNA 210 BLOOD LEVEL; PATIENT MONITORING; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RNA ANALYSIS; TUMOR INVASION; UPREGULATION; BLADDER TUMOR; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TUMOR CELL LINE; TUMOR RECURRENCE;

AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84941992158     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135168     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008;5(2):71-96. doi: 10.3322/CA.2007.0010 PMID: 18287387.
2. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA: the journal of the American Medical Association. 2006;295(3):299-305. doi: 10.1001/jama.295.3.299 PMID: 16418465.
3. Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU international. 2006;97(5):997-1001. doi: 10.1111/j.1464-410X.2006.06036.x PMID: 16542342.
4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. European urology. 2008;54(2):303-14. doi: 10.1016/j.eururo.2008.04.051 PMID: 18468779.
5. Whelan P. Bladder cancer-contemporary dilemmas in its management. European urology. 2008;53(1):24-6. doi: 10.1016/j.eururo.2007.08.056 PMID: 17889428.
6. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61(1):109-18; discussion 18. PMID: 12559279.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. PMID: 21376230. doi: 10.1016/j.cell.2011.02.013
8. Hu G, Chen D, Li X, Yang K, Wang H, Wu W. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer biology & therapy. 2010;10(2):190-7. PMID: 20505319.
9. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Molecular cancer therapeutics. 2009;8(5):1067-74. PMID: 19435867. doi: 10.1158/1535-7163. MCT-08-0592
10. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell research. 2008;1(10):997-1006. doi: 10.1038/cr.2008.282 PMID: 18766170.
11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(30):10513-8. doi: 10.1073/pnas.0804549105 PMID: 18663219; PubMed Central PMCID: PMC2492472.
12. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International journal of oncology. 2012;41(5):1871-8. doi: 10.3892/ijo.2012.1622 PMID: 22961325.
13. Redova M, Sana J, Slaby O. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future oncology. 2013;9(3):387-402. doi: 10.2217/fon. 12.192 PMID: 23469974.
14. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Medicinal research reviews. 2012;32(2):326-48. doi: 10.1002/med.20215 PMID: 22383180.
15. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer science. 2010;101(10):2087-92. doi: 10.1111/j.1349-7006.2010. 01650.x PMID: 20624164.
16. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. British journal of cancer 2013. p. 361-9. doi: 10.1038/bjc.2012.546 PMID: 23329235
17. Qu A, Du L, Yang Y, Liu H, Li J, Wang L, et al. Hypoxia-Inducible MiR-210 Is an Independent Prognostic Factor and Contributes to Metastasis in Colorectal Cancer. PloS one. 2014;9(3):e90952. doi: 10.1371/journal.pone.0090952 PMID: 24632577; PubMed Central PMCID: PMC3954583.
18. Li L, Huang K, You Y, Fu X, Hu L, Song L, et al. Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. International journal of oncology. 2014;44(6):2111-20. doi: 10.3892/ijo.2014.2368 PMID: 24715221.
19. Li X, Chen J, Hu X, Huang Y, Li Z, Zhou L, et al. Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events. PloS one. 2011;6(7):e22570. doi: 10.1371/journal.pone.0022570 PMID: 21799901; PubMed Central PMCID: PMC3143156.
20. Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, Stathopoulos EN, et al. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. The Journal of urology. 2012;188(2):615-23. doi: 10.1016/j.juro.2012.03.122 PMID: 22704449.
21. Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. International journal of cancer Journal international du cancer. 2013;132(11):2479-91. doi: 10.1002/ijc.27949 PMID: 23169479.
22. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012;118(10):2603-14. doi: 10.1002/cncr.26565 PMID: 22370716; PubMed Central PMCID: PMC3864019.
23. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clinical chemistry. 2011;57(1):84-91. doi: 10. 1373/clinchem.2010.151845 PMID: 21036945.
24. Wang L, Liu Y, Du L, Li J, Jiang X, Zheng G, et al. Identification and validation of reference genes for the detection of serum microRNAs by reverse transcriptionquantitative polymerase chain reaction in patients with bladder cancer. Molecular medicine reports. 2015. doi: 10.3892/mmr.2015.3428 PMID: 25738263.
25. Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P, et al. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PloS one. 2012;7(12):e52280. doi: 10.1371/journal.pone.0052280 PMID: 23284967; PubMed Central PMCID: PMC3524115.
26. Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta paediatrica. 2007;96(5):644-7. doi: 10.1111/j.1651-2227.2006.00178.x PMID: 17376185.
27. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating micro-RNA. Nucleic acids research. 2011;39(16):7223-33. doi: 10.1093/nar/gkr254 PMID: 21609964; PubMed Central PMCID: PMC3167594.
28. Chan KC, Lo YM. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. British journal of cancer. 2007;96(5):681-5. doi: 10.1038/sj.bjc.6603625 PMID: 17311021; PubMed Central PMCID: PMC2360081.
29. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nature medicine. 2008;14(9):985-90. doi: 10.1038/nm.1789 PMID: 18670422; PubMed Central PMCID: PMC2820391.
30. Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic acids research. 2010;3(1):215-24. doi: 10.1093/nar/gkp857 PMID: 19850715; PubMed Central PMCID: PMC2800221.
31. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, et al. Selective release of micro-RNA species from normal and malignant mammary epithelial cells. PloS one. 2010;5(10):e13515. doi: 10.1371/journal.pone.0013515 PMID: 20976003; PubMed Central PMCID: PMC2958125.
32. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell death and differentiation. 2011;1(3):465-78. doi: 10.1038/cdd.2010. 119 PMID: 20885442; PubMed Central PMCID: PMC3131992.
33. Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, et al. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol. 2013;34(1):481-91. PMID: 23150176. doi: 10.1007/s13277-012-0573-2
34. Zhao A, Li G, Peoc'h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Experimental and molecular pathology. 2013;94(1):115-20. doi: 10.1016/j.yexmp. 2012.10.005 PMID: 23064048.
35. Varga J, Wohlgethan JR. The clinical and biochemical spectrum of hereditary amyloidosis. Seminars in arthritis and rheumatism. 1988;1(1):14-28. PMID: 2847318.
36. Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N, et al. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. The Journal of biological chemistry. 2007;282(17):12363-7. doi: 10.1074/jbc. C700015200 PMID: 17344217.